Obesity
Conditions
Keywords
Obesity
Brief summary
The enteroendocrine system is composed from different cells along the different parts of the gastrointestinal tract, secreting diverse hormones and bariatric surgery alters intestinal hormone secretion, affecting glycemic control and weight. The aim of the study is to characterize the composition and secretory profile of enteroendocrine cells in the obese, non-obese and non-obese post bariatric surgery.
Detailed description
Obesity and Diabetes Mellitus (DM) impose a significant burden of morbidity on many individuals around the world. In recent years, the enteroendocrine cells system with its diverse hormones (Glucagon, GLP-1, GIP and others) was increasingly recognized as a key player in obesity and DM homeostasis. Bariatric surgery induces weight loss as well as an improvement in glycemic control often leading to diabetes reversal and occasionally to postprandial hypoglycemic events. The aim of the study is to characterize the composition and secretory profile of enteroendocrine cells in the obese, non-obese and non-obese post bariatric surgery.
Interventions
None listed
Sponsors
Hadassah Medical Organization
Dr. Ofir Harnoy MD
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
* \>18 years * BMI\>= 35 or BMI\<=25 or 6-12 months after RYGB surgery
Exclusion criteria
* Known HIV infection * Any NSAID'S usage in the last 3 months * Known Celiac disease * Concomitant disease with potential small bowel or colonic involvement (Tb, sarcoidosis, IBD, microscopic colitis etc') * Pregnancy * Participation in another clinical trial * Any use of medications known to modulate glucagon levels such as GLP1 analogs, DPP4 inhibitors and/or SGLT2 inhibitors. * Insulin-treated patients. * Declined to sign an informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterization the composition of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery. | 3 years | The number of somatostatin, proglucagon and serotonin positive cells in the terminal ileum and Colon by immunohistochemistry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characterization the secretory profile of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery. | 4 YEARS. | Total hormonal content of somatostatin, proglucagon and serotonin will be quantified using mRNA level qunatitation |
Other
| Measure | Time frame | Description |
|---|---|---|
| Characterization the secretory profile of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery. | 4 years | Total hormonal content of somatostatin, proglucagon and serotonin will be quantified using ELISA. |
| Characterization the location of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery. | 4 years. | The location of somatostatin, proglucagon and serotonin will be quantified using ELISA. |
Countries
Israel
Outcome results
None listed